Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × nanocis × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡